PLGA-Rhodamine from PolySciTech used in development of nanoparticle for Tuberculosis treatment

Tuberculosis is a fatal disease which can be treated by specific antibiotic drugs. Due to poor bioavailability and localization, these drugs are typically administered at high doses which can lead to liver damage. Recently, researchers at Université Paris-Sud (France) and Universidade Federal de Ouro Preto (Brazil) used PLGA-Rhodamine (AV011) from PolySciTech (www.polyscitech.com) to generate fluorescently traceable nanoparticles for targeted TB treatment. This research holds promise to provide for improved therapy against tuberculosis with less liver damage. Read more: Carneiro, Simone Pinto, Laurence Moine, Barbara Tessier, Valerie Nicolas, Orlando DH dos Santos, and Elias Fattal. "Pyrazinoic acid-Poly (malic acid) biodegradable nanoconjugate for efficient intracellular delivery." Precision Nanomedicine 2, no. 3 (2019): 303-317. https://precisionnanomedicine.com/api/v1/articles/9660-pyrazinoic-acid-poly-malic-acid-biodegradable-nanoconjugate-for-efficient-intracellular-delivery.pdf

“Abstract: Tuberculosis is an infectious disease affecting mostly lungs, that is still considered a health global problem as it causes millions of deaths worldwide. Current treatment is effective but associated with severe adverse effects due to the high doses of each anti-tuberculosis drug daily administrated by oral therapy. For the first time, a pyrazinoic acid (PA) biodegradable nanoconjugate was synthesized and developed for pulmonary administration in an attempt to reduce the administered doses by achieving a high drug payload and controlled release at the target site. The conjugate was synthesized by coupling pyrazinoic acid on carboxylic groups of poly(malic acid), which is a biodegradable and biocompatible polymer, and posteriorly self-assembled into nanoconjugates. Characterization confirmed the formation of nanometric, spherical and negatively charged pyrazinoic acid nanoconjugate (NC-PA). NC-PA was stable for 60 days at 4 and 37°C and able to deliver PA in a sustained release manner over time. On macrophages, they exhibited no cell toxicity for a wide range of concentrations (from 1 to 100 μg/mL), demonstrating the safety of NC-PA. In addition, the nanoconjugate was efficiently taken up by RAW 264.7 cells over 6 hours reaching a maximum value after 3 hours of incubation. In conclusion, innovative nanoconjugates are a promising alternative to deliver drugs directly to the lungs and contributing to improving tuberculosis therapy.”